Texas 2017 - 85th Regular

Texas House Bill HB1067 Latest Draft

Bill / Introduced Version Filed 01/17/2017

Download
.pdf .doc .html
                            85R4901 DMS-D
 By: Meyer H.B. No. 1067


 A BILL TO BE ENTITLED
 AN ACT
 relating to newborn screening tests for adrenoleukodystrophy.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  The heading to Chapter 33, Health and Safety
 Code, is amended to read as follows:
 CHAPTER 33. ADRENOLEUKODYSTROPHY, PHENYLKETONURIA, OTHER HERITABLE
 DISEASES, HYPOTHYROIDISM, AND CERTAIN OTHER DISORDERS
 SECTION 2.  Section 33.001, Health and Safety Code, is
 amended to read as follows:
 Sec. 33.001.  DEFINITIONS. In this chapter:
 (1)  "Adrenoleukodystrophy" means an inherited
 condition that results in an abnormality in the structure or
 function of the brain and causes severe, life-threatening symptoms.
 (2)  "Birthing facility" means an inpatient or
 ambulatory health care facility that offers obstetrical or newborn
 care services.  The term includes:
 (A)  a hospital licensed under Chapter 241 that
 offers obstetrical services;
 (B)  a birthing center licensed under Chapter 244;
 (C)  a children's hospital; or
 (D)  a facility that provides obstetrical
 services and is maintained and operated by this state or an agency
 of this state.
 (3) [(1-a)]  "Critical congenital heart disease" means
 an abnormality in the structure or function of the heart that exists
 at birth, causes severe, life-threatening symptoms, and requires
 medical intervention within the first few hours, days, or months of
 life.
 (4) [(1-b)]  "Heritable disease" means an inherited
 disease that may result in intellectual [mental] or physical
 disability [retardation] or death.
 (5) [(2)]  "Hypothyroidism" means a condition that may
 cause severe intellectual disability [mental retardation] if not
 treated.
 (6) [(3)]  "Other benefit" means a benefit, other than
 a benefit under this chapter, to which an individual is entitled for
 the payment of the costs of services.  The term includes:
 (A)  benefits available under:
 (i)  an insurance policy, group health plan,
 or prepaid medical care plan;
 (ii)  Title XVIII of the Social Security Act
 (42 U.S.C. Section 1395 et seq.);
 (iii)  Title XIX of the Social Security Act
 (42 U.S.C. Section 1396 et seq.);
 (iv)  the United States Department of
 Veterans Affairs;
 (v)  the TRICARE program of the United
 States Department of Defense; or
 (vi)  workers' compensation or any other
 compulsory employers insurance program;
 (B)  a public program created by federal or state
 law or by ordinance or rule of a municipality or political
 subdivision of the state, except those benefits created by the
 establishment of a municipal or county hospital, a joint
 municipal-county hospital, a county hospital authority, a hospital
 district, or by the facilities of a publicly supported medical
 school; and
 (C)  benefits resulting from a cause of action for
 health care expenses, or a settlement or judgment based on the cause
 of action, if the expenses are related to the need for services
 provided under this chapter.
 (7) [(4)]  "Phenylketonuria" means an inherited
 condition that may cause severe intellectual disability [mental
 retardation] if not treated.
 (8) [(5)]  "Screening test" means a rapid analytical
 procedure to determine the need for further diagnostic evaluation.
 SECTION 3.  Sections 33.002(a) and (c), Health and Safety
 Code, are amended to read as follows:
 (a)  The department shall carry out a program to combat
 morbidity, including intellectual disability [mental retardation],
 and mortality in persons who have adrenoleukodystrophy,
 phenylketonuria, other heritable diseases, or hypothyroidism.
 (c)  The department shall establish and maintain a
 laboratory to:
 (1)  conduct experiments, projects, and other
 activities necessary to develop screening or diagnostic tests for
 the early detection of adrenoleukodystrophy, phenylketonuria,
 other heritable diseases, and hypothyroidism;
 (2)  develop ways and means or discover methods to be
 used to prevent or treat adrenoleukodystrophy, phenylketonuria,
 other heritable diseases, and hypothyroidism; and
 (3)  serve other purposes considered necessary by the
 department to carry out the program.
 SECTION 4.  Section 33.011(a), Health and Safety Code, is
 amended to read as follows:
 (a)  The physician attending a newborn child or the person
 attending the delivery of a newborn child that is not attended by a
 physician shall cause the child to be subjected to screening tests
 approved by the department for adrenoleukodystrophy,
 phenylketonuria, other heritable diseases, hypothyroidism, and
 other disorders for which screening is required by the department.
 SECTION 5.  Section 33.014(a), Health and Safety Code, is
 amended to read as follows:
 (a)  If, because of an analysis of a specimen submitted under
 Section 33.011, the department reasonably suspects that a newborn
 child may have adrenoleukodystrophy, phenylketonuria, another
 heritable disease, hypothyroidism, or another disorder for which
 the screening tests are required, the department shall notify the
 person who submits the specimen that the results are abnormal and
 provide the test results to that person.  The department may notify
 one or more of the following that the results of the analysis are
 abnormal and recommend further testing when necessary:
 (1)  the physician attending the newborn child or the
 physician's designee;
 (2)  the person attending the delivery of the newborn
 child that was not attended by a physician;
 (3)  the parents of the newborn child;
 (4)  the health authority of the jurisdiction in which
 the newborn child was born or in which the child resides, if known;
 or
 (5)  physicians who are cooperating pediatric
 specialists for the program.
 SECTION 6.  Section 33.031(a), Health and Safety Code, is
 amended to read as follows:
 (a)  All newborn children and other individuals under 21
 years of age who have been screened, have been found to be
 presumptively positive through the newborn screening program for
 adrenoleukodystrophy, phenylketonuria, other heritable diseases,
 hypothyroidism, or another disorder for which the screening tests
 are required, and may be financially eligible may be referred to the
 department's services program for children with special health care
 needs.
 SECTION 7.  Section 33.032(a), Health and Safety Code, is
 amended to read as follows:
 (a)  Within the limits of funds available for this purpose
 and in cooperation with the individual's physician, the department
 may provide services directly or through approved providers to
 individuals of any age who meet the eligibility criteria specified
 by department rules on the confirmation of a positive test for
 adrenoleukodystrophy, phenylketonuria, other heritable diseases,
 hypothyroidism, or another disorder for which the screening tests
 are required.
 SECTION 8.  The heading to Chapter 1359, Insurance Code, is
 amended to read as follows:
 CHAPTER 1359. FORMULAS FOR INDIVIDUALS WITH ADRENOLEUKODYSTROPHY,
 PHENYLKETONURIA, OR OTHER HERITABLE DISEASES
 SECTION 9.  Section 1359.001, Insurance Code, is amended to
 read as follows:
 Sec. 1359.001.  DEFINITIONS. In this chapter:
 (1)  "Adrenoleukodystrophy" means an inherited
 condition that results in an abnormality in the structure or
 function of the brain and causes severe, life-threatening symptoms.
 (2)  "Heritable disease" means an inherited disease
 that may result in intellectual [mental] or physical disability
 [retardation] or death.
 (3) [(2)]  "Phenylketonuria" means an inherited
 condition that, if not treated, may cause severe intellectual
 disability [mental retardation].
 SECTION 10.  Section 1359.003(a), Insurance Code, is amended
 to read as follows:
 (a)  A group health benefit plan must provide coverage for
 formulas necessary to treat adrenoleukodystrophy, phenylketonuria,
 or a heritable disease.
 SECTION 11.  Section 203.355(c), Occupations Code, is
 amended to read as follows:
 (c)  The laboratory services must include the performance of
 the standard serological tests for syphilis and the collection of
 blood specimens for newborn screening tests for
 adrenoleukodystrophy, phenylketonuria, hypothyroidism, and other
 heritable diseases as required by law.
 SECTION 12.  As soon as practicable after the effective date
 of this Act, the Department of State Health Services shall
 implement the changes in law made by this Act to the newborn
 screening program under Chapter 33, Health and Safety Code.
 SECTION 13.  This Act takes effect September 1, 2017.